Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for Legend Biotech (LEGN) over the last 5 years, with Dec 2024 value amounting to $46.9 million.

  • Legend Biotech's Current Deferred Revenue rose 23.09% to -$28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.8 million, marking a year-over-year increase of 23.09%. This contributed to the annual value of $46.9 million for FY2024, which is 11.58% down from last year.
  • According to the latest figures from FY2024, Legend Biotech's Current Deferred Revenue is $46.9 million, which was down 11.58% from $53.0 million recorded in FY2023.
  • Legend Biotech's Current Deferred Revenue's 5-year high stood at $53.0 million during FY2023, with a 5-year trough of -$60.6 million in FY2021.
  • Moreover, its 2-year median value for Current Deferred Revenue was $49.9 million (2023), whereas its average is $49.9 million.
  • Data for Legend Biotech's Current Deferred Revenue shows a maximum YoY plummeted of 218.84% (in 2020) over the last 5 years.
  • Legend Biotech's Current Deferred Revenue (Yearly) stood at -$55.0 million in 2020, then fell by 10.23% to -$60.6 million in 2021, then reached $53.0 million in 2023, then declined by 11.58% to $46.9 million in 2024.